MedTrace Logo

Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

NCT05489120 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2025-01-29

No results posted yet for this study

Summary

The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.

Conditions

  • Chronic Kidney Disease Stage 3B
  • Chronic Kidney Disease stage4
  • Chronic Kidney Disease Stage 5
  • Chronic Kidney Disease Stage 3A

Interventions

OTHER

Consumption of FLAVIS

Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.

Sponsors & Collaborators

  • Slb Pharma

    collaborator OTHER

  • Dr. Schär AG / SPA

    lead INDUSTRY

Principal Investigators

  • Laetitia Koppe, Dr · HCL

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-06
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05489120 on ClinicalTrials.gov